|
1) Breda L, Del Torto M, De Sanctis S, et al. Biologics in childrenʼs autoimmune disorders: efficacy and safety. Eur J Pediatr. 2010 Jun 17. [Epub ahead of print]
|
|
|
|
|
2) Weiss JE, Eberhard A, Chowdhury D, et al. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol. 2004; 31; 808-10
|
|
|
|
|
3) Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005; 146: 662-7
|
|
|
|
|
4) Saji T, Kemmotsu Y. Infliximab for Kawasaki syndrome [reply]. J Pediatr. 2006; 149: 426
|
|
|
|
|
|
5) Stenbog EV, Windelborg B, Horlyck A, et al. The effect of TNFalpha blockade in complicated, refractory Kawasaki disease. Scand J Rheumatol. 2006; 35: 318-21
|
|
|
|
|
|
6) OʼConnor MJ, Saulsbury FT. Incomplete and atypical Kawasaki disease in a young infant: Severe, recalcitrant disease responsive to infliximab. Clin Pediatr. 2007; 46: 345-8
|
|
|
|
|
|
7) Oishi T, Fujieda M, Shiraishi T, et al. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm. Circ J. 2008; 72: 850-2
|
|
|
|
|
8) Girish M, Subramaniam G. Infliximab treatment in refractory Kawasaki syndrome. Indian J Pediatr. 2008; 75: 521-2
|
|
|
|
|
|
9) Burns JC, Best BM, Mas PD, et al. Infliximab treatment of Intravenous immunoglobulin-Resistant Kawasaki disease. J Pediatr. 2008; 153: 833-8
|
|
|
|
|
|
10) Brogan RJ, Eleftheriou D, Gnanapragasam J, et al. Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report. Pediatric Rheumatology. 2009; 7: 1-5
|
|
|
|
|
|
11) 佐地 勉, 中川雅生, 小川俊一, 他. 委員会報告: 急性期川崎病のIVIG不応例に対する生物学的製剤infliximab(レミケード)使用の調査報告-その安全性と有用性について-. 日本小児循環器学会雑誌. 2009; 25: 268-9
|
|
|
|
|
|
12) Song MS, Lee BS, Sohn S, et al. Infliximab treatment for refractory Kawasaki disease in Korean children. Korean Circ J. 2010; 40: 334-8
|
|
|
|
|
|
13) Shirley DA, Stephens I. Primary treatment of incomplete Kawasaki disease with infliximab and methylpredonisolone in a patient with a contraindication to intravenous immune globulin. Pediatr Infect Dis J. 2010; 29: 978-9
|
|
|
|
|
|
14) Hirono K, Kemmotsu Y, Wittkowski H, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res. 2009; 65: 696-701
|
|
|
|
|
|
15) Son MB, Gauvreau K, Ma L, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009; 124: 1-8
|
|
|
|
|
|
16) Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther. 2010; 8: 197-203
|
|
|
|
|
|
17) Hii-Yuen JS, Duong TT, Yeung RSM. THF-α is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol. 2006; 176: 6294-301
|
|
|
|
|
|
18) Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol. 2009; 36: 635-41
|
|
|
|
|
|
19) Molloy ES, et al. Anti-tumor necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis. 2008; 67: 1567-9
|
|
|
|
|
|
20) Koh MJ, Tay YK. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Curr Opin Pediatr. 2009; 21: 505-10
|
|
|
|
|
|
21) Ruperto N, Lovell DJ, Cuttica R, et al. Padiatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaboratives Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007; 56: 3096-106
|
|
|
|
|
|
22) Saag KG, Teng GG, Patkar M, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis & Rheumatizm. 2008; 59: 762-84
|
|
|
|
|
|
23) Horneff G. Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. Z Rheumatol. 2010; 69: 516-26
|
|
|
|
|
|
24) Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor-alpha blockers and malignancy in children: Forty-right cases reported to the Food and Drug Administration. Arthritis Rheum. 2010; 62: 2517-26
|
|
|
|
|
|
25) Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59: 762-84
|
|
|
|
|
|
26) Lahdenne P, Wikstrom Am, Aalto K, et al. Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res. 2010; 62: 785-90
|
|
|
|
|
|
27) Gerloni V, Pontikaki I, Gattinnara M, et al. Focus on adverse events of tumour necrosis factorα blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Am Rheum Dis. 2008; 67: 1145-52
|
|
|
|
|
|
28) Ruperto N, Lovell DJ, Cuttica R, et al. Long-term Efficacy and safety of Infliximab plus Methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: Findings from an open-label treatment extension. Ann Rheum Dis. 2010; 69: 718-22
|
|
|
|
|
|
29) de Ridder L, Rings EH, Damen GM, et al. Infliximab dependency in pediatric Crohnʼs disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis. 2008; 14: 353-8
|
|
|
|
|